Deutsche Bank AG Has $1.90 Million Stake in AngioDynamics, Inc. $ANGO

Key Points

• Deutsche Bank AG significantly increased its stake in AngioDynamics, acquiring an additional 163,002 shares, raising its ownership to a total of 201,897 shares, valued at approximately $1.9 million.
• AngioDynamics reported earnings of ($0.03) per share for the last quarter, surpassing analyst expectations of ($0.12), and recorded a 13% increase in revenue compared to the previous year.
• Several analysts have issued "buy" ratings for AngioDynamics, with target prices ranging from $16.00 to $24.00, indicating strong market optimism for the stock.

Deutsche Bank AG raised its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 419.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 201,897 shares of the medical instruments supplier's stock after acquiring an additional 163,002 shares during the period. Deutsche Bank AG owned approximately 0.50% of AngioDynamics worth $1,896,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ANGO. ProShare Advisors LLC acquired a new stake in AngioDynamics in the 4th quarter valued at $100,000. Graham Capital Management L.P. acquired a new position in shares of AngioDynamics in the fourth quarter worth $106,000. OneDigital Investment Advisors LLC boosted its holdings in AngioDynamics by 14.0% during the fourth quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier's stock valued at $111,000 after acquiring an additional 1,490 shares during the period. Cerity Partners LLC lifted its stake in shares of AngioDynamics by 22.0% in the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock valued at $121,000 after buying an additional 2,333 shares during the period. Finally, Nebula Research & Development LLC bought a new position in AngioDynamics during the fourth quarter worth about $125,000. Institutional investors and hedge funds own 89.43% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have commented on ANGO shares. Lake Street Capital assumed coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They set a "buy" rating and a $24.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of AngioDynamics in a research note on Wednesday, July 16th. Wall Street Zen upgraded shares of AngioDynamics from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Finally, Canaccord Genuity Group boosted their price target on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 16th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $19.00.

AngioDynamics Stock Up 2.2%

Shares of NASDAQ ANGO traded up $0.21 during midday trading on Tuesday, reaching $9.89. 149,885 shares of the stock were exchanged, compared to its average volume of 624,314. AngioDynamics, Inc. has a twelve month low of $5.83 and a twelve month high of $13.50. The firm has a 50-day simple moving average of $9.23 and a two-hundred day simple moving average of $9.57. The firm has a market cap of $401.83 million, a price-to-earnings ratio of -11.93 and a beta of 0.67.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%.The business had revenue of $80.16 million during the quarter, compared to analysts' expectations of $74.26 million. During the same quarter last year, the business posted ($0.06) EPS. The business's quarterly revenue was up 13.0% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. Research analysts expect that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.